Recent Advancement in Management of H. Pylori Induced PUD
Fuente:
Zenodo
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Recurso digital |
| Pubblicazione: |
Zenodo
2025
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1866901118114594816 |
|---|---|
| author | Azeem Bagwan, Bhosale Rohit |
| author_facet | Azeem Bagwan, Bhosale Rohit |
| contents | <p><span>Helicobacter pylori (H. pylori) is a major cause of peptic ulcer disease (PUD) and gastric cancer. Since its identification, advancements in eradication therapies have significantly improved patient outcomes. This review discusses recent developments in the management of H. pylori infection, including improved diagnostic techniques, novel treatment regimens, and innovative therapeutic approaches such as nanotechnology-based drug delivery and probiotic applications. Traditional triple therapy is losing efficacy due to rising antibiotic resistance, leading to the adoption of quadruple therapy and emerging therapies such as vonoprazan-based regimens and nanoparticle-based antibiotics. Additionally, the role of non-pharmacological interventions, including lifestyle modifications and dietary changes, is explored. The review highlights the need for personalized treatment strategies, new antimicrobial agents, and innovative drug delivery systems to enhance eradication rates and reduce treatment-related complications.</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_14992264 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Recent Advancement in Management of H. Pylori Induced PUD Azeem Bagwan, Bhosale Rohit Helicobacter pylori, peptic ulcer disease, antibiotic resistance, eradication therapy, quadruple therapy, nanotechnology, probiotics, vonoprazan, drug delivery, gastric cancer <p><span>Helicobacter pylori (H. pylori) is a major cause of peptic ulcer disease (PUD) and gastric cancer. Since its identification, advancements in eradication therapies have significantly improved patient outcomes. This review discusses recent developments in the management of H. pylori infection, including improved diagnostic techniques, novel treatment regimens, and innovative therapeutic approaches such as nanotechnology-based drug delivery and probiotic applications. Traditional triple therapy is losing efficacy due to rising antibiotic resistance, leading to the adoption of quadruple therapy and emerging therapies such as vonoprazan-based regimens and nanoparticle-based antibiotics. Additionally, the role of non-pharmacological interventions, including lifestyle modifications and dietary changes, is explored. The review highlights the need for personalized treatment strategies, new antimicrobial agents, and innovative drug delivery systems to enhance eradication rates and reduce treatment-related complications.</span></p> |
| title | Recent Advancement in Management of H. Pylori Induced PUD |
| topic | Helicobacter pylori, peptic ulcer disease, antibiotic resistance, eradication therapy, quadruple therapy, nanotechnology, probiotics, vonoprazan, drug delivery, gastric cancer |
| url | https://doi.org/10.5281/zenodo.14992264 |